Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for skin lesions in Adult T-cell leukemia-lymphoma (ATLL)
jRCTs071220095Active, not recruiting
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of hydroxychloroquine in adult T-cell leukemia-lymphoma (ATLL). Primary endpoint: Best overall response by mSWAT up to 24 weeks. Started May 2023; status: active, not recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCTs071220095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071220095.